VTGN / VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Mark Flather - VP of IR Sh more_horizontal

Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Mast more_horizontal

Vistagen Therapeutics (NASDAQ: VTGN ) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer more_horizontal

Are you looking for penny stocks to buy? Are you grappling with the push and pull of skeptics saying penny stocks aren't worth it or penny stocks are more_horizontal

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming more_horizontal

VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2023 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Mark Flather - Vice Presi more_horizontal

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. D more_horizontal

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treat more_horizontal